Aims Guidelines recommend testing HbA 1c every 3-6 months in people with diabetes. In the United Kingdom (UK), primary care clinics are financially incentivized to monitor HbA 1c at least annually and report proportions of patients meeting targets on 31 March. We explored the hypothesis that this reporting deadline may be associated with overfrequent or delayed HbA 1c testing.
Introduction
Internationally, guidelines recommend testing HbA 1c every 3-6 months in people with Type 2 diabetes depending on recent therapy changes and glycaemic targets [1, 2] . Prior to 2015, the United Kingdom's (UK) National Institute of Health and Care Excellence (NICE) recommended testing every 2-6 months [3] . In the UK, most HbA 1c monitoring takes place in primary care and samples are analysed in a central hospital laboratory. The UK's Quality and Outcomes Framework (QOF) is a reward scheme using financial reimbursement to incentivize general practitioners (GPs) to achieve target patient health indicators, reporting data annually on 31 March. For diabetes, GP practices receive reimbursement for monitoring of HbA 1c every 12 months and for the proportion of their patients achieving pre-defined HbA 1c thresholds [4, 5] . These incentives should encourage monitoring on at least an annual basis.
Changes in glycaemic control, even after treatment change, take 2-3 months to be reflected in HbA 1c [6] , and guidelines do not recommend retesting HbA 1c within 2 months. Studies from different countries, however, report that HbA 1c is often tested more frequently or not frequently enough [7] [8] [9] [10] [11] , suggesting that resources are not always used optimally even though healthcare budgets are facing pressure to reduce costs. Arguably, monitoring HbA 1c more frequently may be clinically appropriate for some people with diabetes, particularly those who have had a recent medication change [6] or those with uncontrolled diabetes. Care delivery and HbA 1c testing may vary across GP practices [12] or regions of the UK [13] , or differ according to an individual's characteristics or comorbidities [14, 15] .
We recently carried out an analysis of hospital laboratory data and found that timing of HbA 1c testing intervals was less likely to be aligned with guidelines in the four months prior to the QOF reporting deadline on 31 March [16] . In this work, we hypothesize that both an individual's previous HbA 1c and the reporting deadline at the end of the administrative year are associated with over-frequent or delayed HbA 1c testing in national data in the UK. We also examine whether there are regional differences across the UK and whether other pre-defined participant or GP practicelevel variables may be associated with very frequent or delayed HbA 1c testing intervals. We used the Clinical Practice Research Datalink (CPRD), a governmental database providing anonymized data from UK primary care for medical research.
Methods
This study presents research from a protocol approved by the Independent Scientific Advisory Committee (ISAC) to the Medicines and Healthcare Products Regulatory Agency (protocol 15_099). The approved protocol was made available to the journal and reviewers during peer review. Ethical approval for observational research using the CPRD with approval from ISAC has been granted by a National Research Ethics Service committee (Trent MultiResearch Ethics Committee, reference 05/MRE04/87).
We used data from 100 000 adults with diabetes randomly selected from the CPRD database over a 10-year period from 1 January 2005 to 31 December 2014. The sample size was estimated from odds ratios (ORs) derived from an analysis of hospital laboratory data [16] 
Data management
Age was set as the age at baseline. For covariates that could change over time, such as BMI total cholesterol or SBP, the latest recorded value from up to two years prior to the baseline test date was used; cases in which no values were available within this time frame were treated as missing data. Those with missing data were not included in the analysis for that variable. Having a diagnosis of microalbuminuria was set at baseline levels. Participants were coded as receiving lipid-lowering medication or antihypertensive medication for the duration of follow-up if they had a product code for these at any time prior to baseline date. Those with missing data on smoking were classed as nonsmokers. Diabetes medication type was classified as diet, oral, insulin or both oral and insulin-treated, based on the medication that was prescribed most frequently for that individual. Injectable non-insulin medications such as exenatide were categorized with 'oral' medication. Medication change was defined as addition of a new type of diabetes medication at or following the previous HbA 1c test. Participants remained in the analysis until the end of follow-up on 31 December 2014, or when they left the surgery, died or developed cancer or end-stage renal disease. • This is the largest analysis to explore factors associated with timings of HbA 1c tests in people with diabetes in the UK.
• Timings of repeat HbA 1c tests are associated with the Quality and Outcomes Framework reporting deadline and participants' previous HbA 1c .
• People with higher HbA 1c were more likely to be retested within 60 days compared with those with wellcontrolled diabetes.
• Financial incentives appear to result in more overfrequent or catch-up HbA 1c testing in the months approaching the reporting deadline than other months of the year in attempts to meet targets.
• This could have implications for future target-based incentive programmes. Because of the nested structure of the data (HbA 1c test interval, participant and GP practice), three-level mixed effects logistic regression models were used with random effect elements for participant and GP practice. The analyses were run for the full cohort, and separately for those with Type 1 (n = 6208) and Type 2 diabetes (n = 86 495).
A hypothesis-generating analysis was then used to examine the association of variables that may reflect participant health status or changes in treatment with retesting HbA 1c at < 60-day or > 366-day test intervals. The exposure variables examined were: age, sex, absolute change in HbA 1c between the two previous measures, year of test, BMI, SBP, total cholesterol, smoking status, diagnosis of microalbuminuria, type of diabetes, having had a medication change at the previous visit, having a prescription for lipid-lowering or antihypertensive medication, geographic location of the GP practice (Scotland, Wales, England, and regionally within England) and medications taken (no medication prescription, insulin, oral medication or both). The analyses were run for the full cohort, and separately for those with Type 2 diabetes.
ORs and 95% confidence intervals (95% CI) were reported for each variable from the multivariate models. Because of potential bias of the longitudinal model to favour shorter testing intervals (with longer intervals disproportionately likely to be censored by end of follow-up), sensitivity analyses were carried out using two-level logistic regression models based on a single random measurement selected from each participant, to ensure that results were robust. Further sensitivity analyses using multinomial logistic regression models and different comparator groups were carried out detailed in Doc. S1. A P-value < 0.05 was considered significant.
Results
The cohort of 100 000 participants had a total of 953 634 HbA 1c tests over the 10 years of follow-up. (Fig. 1a) . Fewer tests were performed in April, August and December than in other months of the year (Fig. 1b) . Results from the logistic regression models are shown in Table 2 . Both pre-specified primary outcomes of HbA 1c test date between December and March and having a previous HbA 1c > 58 mmol/mol (7.5%) were found to be significantly associated with timing of HbA 1c tests for the full cohort and separately for Type 1 and Type 2 diabetes.
Short testing interval (< 60 days)
In the univariate analysis, test intervals of < 60 days were more common during December to March than in other months of the year (OR 1.06, 95% CI 1.05-1.08; P < 0.0001) and those with a previous HbA 1c > 58 mmol/ mol (7.5%) had significantly higher odds of receiving a repeat HbA 1c test within 60 days compared with those with HbA 1c ≤ 58 mmol/mol (7.5%) (OR 2.21, 95% CI 2.18-2.25; P < 0.0001) ( Table 2) . Results were similar for those with Type 1 and Type 2 diabetes, inclusion of both variables in the analysis (Table 2) and after adjustment for all predefined covariates (Table 3) . Sensitivity analyses using different statistical models were broadly similar to the main analysis (Doc. S1). The sensitivity analysis, using a single random test for each participant, gave results consistent with the main analysis, although time of year was no longer significant due to the smaller sample size (not shown).
Other covariates found to be significantly associated with increased odds of retesting HbA 1c within 60 days were increasing age, higher BMI, a diagnosis of microalbuminuria, (Table 3; Table S1 ). A more recent calendar year, higher SBP, having had a recent medication change and location in the East or West of England or London and the South East compared with the North of England, were all associated with lower odds of retesting HbA 1c within 60 days (Table 3; Table S1 ).
Long testing interval (> 366 days)
Those whose HbA 1c tested between December and March had significantly higher odds of their test being > 366 days from their previous test than those tested at other times of the year (OR 1.07, 95% CI 1.05-1.08; P < 0.0001). Those with a previous HbA 1c > 58 mmol/mol (7.5%) were significantly less likely to have had a test > 1year from the previous test (OR 0.48, 95% CI 0.47-0.49; P < 0.0001). Results were similar for those with Type 1 and Type 2 diabetes, when both variables were included in the analysis (Table 2) and after adjustment for all pre-defined covariates (Table 3) . Sensitivity analyses using different statistical models were broadly similar to the main analysis (Doc. S1). The sensitivity analysis, using a single random test for each participant, gave results consistent with the main analysis, although time of year was no longer significant due to the smaller sample size (not shown).
Other covariates found to be significantly associated with increased odds of retesting HbA 1c > 1 year from the previous test were an increase in HbA 1c between the previous two measurements, increasing test year, higher BMI, higher SBP, higher total cholesterol, being a current smoker compared with non-smokers, having a diagnosis of microalbuminuria, having had a recent medication change and GP practice location in London or the South East of England, compared with the North of England (Table 3; Table S1 ).
Older age, having Type 2 diabetes relative to Type 1 diabetes, taking lipid-lowering or antihypertensive medication, GP practice location in Scotland compared with North of England and taking oral and/or insulin treatment compared with diet-control were significantly associated with a lower odds of retesting HbA 1c > 1 year from the previous test (Table 3; Table S1 ). Results for those with Type 2 diabetes only and the sensitivity analysis using a random measurement from each participant, gave results consistent with the full analysis, but with fewer significant findings (not shown).
Discussion
The frequency of HbA 1c testing is, appropriately, related to the HbA 1c level at the previous visit, as more frequent testing is carried out when HbA 1c is above target. However, the approach of the QOF administrative reporting deadline is also associated with time intervals for HbA 1c testing in the UK. Specifically, there is an increased volume of retesting within 60 days in the 4 months leading up to the deadline. Because a 60-day interval is too short for changes in HbA 1c to reliably reflect change in glycaemic status following a treatment change [2, 3, 6] , this may represent a rush to reduce HbA 1c ahead of the reporting deadline, rather than an optimally timed attempt to assess diabetes control for patient benefit. The same time of year is also associated with an increased rate of testing in those who have not had an HbA 1c test for > 1 year. This may represent the QOF deadline successfully incentivizing a 'catch-up' test in people who might otherwise go untested for longer still. We found evidence that there were differences in rates of HbA 1c testing across the UK, with Scotland and Northern Ireland being most likely to retest HbA 1c very frequently, whereas London and the South East of England were less likely to retest within 60 days. Conversely, GPs in London were more likely to have > 1 year between HbA 1c tests compared with other parts of the UK, and those in Scotland the least likely. These variations in HbA 1c testing across the UK may result from differences in population demographics, deprivation and local resources [13, 17, 18] . The data suggest that retesting > 1 year from the previous test is less common in Scotland than in other parts of the UK. This may be because GPs are proactively inviting their patients to diabetes reviews as part of one of the quality improvement initiatives in Scotland [19] [20] [21] [22] [23] . Crucially, the significant association between HbA 1c testing intervals and times of year suggests that GPs may be following-up those who are late for appointments or not meeting targets more closely in the months before the QOF reporting deadline.
To our knowledge, this is the largest analysis to explore factors associated with timings of HbA 1c tests in the UK, but there are some limitations with this work. Each participant in the analysis had a minimum of three HbA 1c tests, which may have favoured short testing intervals over long testing intervals. To test this, we carried out sensitivity analyses using a randomly selected test interval from each individual and found similar results, suggesting that these findings are robust. We were unable to examine GP-level differences in testing, which might have provided information on differences in practices or professional opinion.
Some findings in the exploratory analyses may not be clinically significant or may be chance findings. However, our main findings, time of year and previous HbA 1c , were pre-specified as the primary hypotheses tested, and were statistically significant in both adjusted and unadjusted analyses.
Although people with some life-threatening conditions were excluded from this analysis, it is acknowledged that some people included in the analysis may have been exempt from QOF due to age, frailty or existing comorbidities [4] making regular monitoring or tight glycaemic control inappropriate or unfeasible, which is a limitation of this work. Our analysis has, however, found that those with microalbuminuria or who were taking lipid-lowering or antihypertensive medications (surrogates for comorbidities) are more likely to be monitored very frequently and less likely to have delayed testing than those without. This is consistent with reports that people with multiple comorbidities receive higher quality care [14, 24, 25] .
We dichotomized the HbA 1c monitoring interval using cutoffs that lay beyond the outer limits of international guidelines and incentive schemes. In doing this we may have missed some trends associated with increasing or decreasing HbA 1c testing interval measured as a continuous outcome.
Previous reports have described HbA 1c testing practices in UK primary care [8, 11, 26] , with outcomes ranging from the numbers of inappropriate test requests [8] to implications of testing frequency on HbA 1c change [11, 26] . Re-testing HbA 1c within very short time intervals may be appropriate for some individuals who had recently been prescribed a new medication to monitor response or adherence [6] . Data from our analysis have shown that retesting HbA 1c within 60 days was more common in participants with the highest HbA 1c . So, although this testing interval is shorter than guidelines recommend, this work suggests that GPs believe that retesting HbA 1c within a short time interval is appropriate for some people.
QOF has been reported to improve performance in GP practices [27] . Our study has found that QOF may be incentivizing GPs to monitor some people more closely to meet targets, but does not tell us how this goes on to affect longer-term outcomes. It is also not clear whether the participants who were more closely monitored in December to March were those who would benefit most from closer monitoring and treatment changes, were 'easy targets' who were already close to one of the QOF thresholds, or were those who were most adherent to appointments and medication.
The long-term health implications for those individuals who do not receive HbA 1c testing aligned with guidelines, may be greatest for those with uncontrolled diabetes who are not receiving annual HbA 1c tests. Exposure to high levels of glycaemia over extended periods increases the risk of diabetes-related complications, which may then result in more consultations for other health-related problems [28] . Although causation cannot be inferred from this analysis, the approach of the QOF deadline is associated with more of those with uncontrolled diabetes receiving their HbA 1c test. These findings suggest that QOF may be encouraging GPs to monitor their patients in attempts to meet targets, but results in more over-frequent or catch-up HbA 1c testing in the months approaching the end of March deadline for reporting indicators of patients' health status. This may have wider implications for those considering introducing incentivebased interventions in the future.
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